

MOMENTA PHARMACEUTICALS INC  
Form 8-K  
June 28, 2018

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 22, 2018**

**Momenta Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-50797**  
(Commission  
File Number)

**04-3561634**  
(IRS Employer  
Identification No.)

**301 Binney Street, Cambridge, MA**  
(Address of Principal Executive Offices)

**02142**  
(Zip Code)

**(617) 491-9700**

(Registrant's telephone number, including area code)

**Not applicable**

## Edgar Filing: MOMENTA PHARMACEUTICALS INC - Form 8-K

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

**Item 8.01. Other Events.**

In connection with a dispute relating to obligations under a manufacturing services agreement between Momenta Pharmaceuticals, Inc. (Momenta) and Human Genome Sciences, Inc. (GSK), the supplier of product for M923, Momenta's proposed biosimilar to HUMIRA® (adalimumab) candidate, Momenta and GSK have come to an understanding regarding Momenta's contractual commitments for the purchase of product batches for M923 through 2022. In addition, as part of the resolution of the dispute, Momenta has agreed to pay GSK \$15 million by August 15, 2018 and \$15 million by July 1, 2019.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MOMENTA PHARMACEUTICALS, INC.**

Date: June 28, 2018

By:

/s/ Craig A. Wheeler  
Craig A. Wheeler

President and Chief Executive Officer